What is Innovation Pharmaceuticals Inc. (IPIX)?

Innovation Pharmaceuticals Inc. (IPIX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of IPIX?

The current price of IPIX is $0.00. Prices are updated in real time on Stocks360.

What is IPIX's price-to-earnings (PE) ratio?

IPIX's trailing twelve-month PE ratio is -0.16, based on current price and earnings per share data available on Stocks360.

What is IPIX's market capitalization?

IPIX's market capitalization is $514,014.00, placing it in the small-cap tier.

Innovation Pharmaceuticals Inc. (IPIX)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$514.01K

PE (TTM)

-0.16

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.49

Day Range

$0.00 – $0.01

52-wk Range

$0.00 – $0.05

Avg Volume

N/A

Volume

12.60K

Innovation Pharmaceuticals Inc. (IPIX) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $514.01K. Trailing PE -0.16. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $0.00 2026-10-27 · $0.00 (+0.00%)

Earnings

Most Recent

Nov 9, 2023

EPS $-0.00 vs est. $1.39

Missed by $1.39

Proprietary Signals

Signal snapshot temporarily unavailable.

About Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Its pipeline targets a range of medical areas, including inflammatory diseases, cancer, dermatology, and infectious conditions. The company's lead drug candidate, Brilacidin, is currently in development for treating oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Furthermore, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound being investigated for ovarian cancer. The company holds a license agreement with Alfasigma S.p.A. and has a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. Established in 2005 and headquartered in Wakefield, Massachusetts, the firm operated as Cellceutix Corporation until its name change to Innovation Pharmaceuticals Inc. in June 2017.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.16×
P/S (TTM)	0.00×
P/B	0.25×
P/FCF (TTM)	-0.24×
EV / EBITDA	0.10×
EV / Sales	0.00×
Earnings Yield	-626.38%
Free Cash Flow Yield	-421.39%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$278.99K
Net Income (TTM)	-$3.22M
Free Cash Flow (TTM)	-$2.11M
Net Debt	-$793.00K
Working Capital	-$3.39M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-93.60%
Return on Invested Capital	-112.55%